5th Annual Targeted Protein Degredation (TPD) Europe

Topics

• From Serendipity to Late Stage Clinical Development: New Update Towards First-In-Class Approval
• Discovery & Early-Stage Development
• Novel Platforms & Screening for High Throughput Targets & E3 Hit Finding for PROTACs
• Preclinical, Translational & Clinical Considerations
• Leveraging Robust Lead Optimisation to Enable Efficacious Translation for PROTACs
• Broadening the Horizon of TPD From Oncology via Alternative Pathways
• Lessons Learned From the Clinic to Bolster Translation of Next Wave of Novel Degraders
• Harnessing Best-in-Class Modeling Systems, Unique Modes of Action, & Tissue-Sparing Ligases to Address Selectivity, Safety, & Efficacy Over Inhibition
• Unravelling Induced Proximity’s Potential to Degrade